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ABSTRACT  
The ubiquitin-proteasome pathway is a crucial connection between aberrant immune system activation, 
systemic inflammation and Cancer Anorexia-Cachexia Syndrome (CACS), a syndrome that culminates in 
hyper-activation of the ubiquitin-proteasome pathway. Angiotensin directly up-regulates this pathway, while 
vitamin D down-regulates it indirectly through the insulin-like growth factor-1 pathway. We investigated the 
genetic predisposition towards CACS in a cancer population, examining Insertion/Deletion (I/D) 
polymorphism of angiotensin-converting enzyme gene and FokI and BsmI polymorphisms of vitamin D 
receptor gene. Sixty-two cancer patients were recruited and divided into three groups: primary cachectic (C1, n 
= 14; dysmetabolic body weight loss ≥5% in 6 months); secondary cachectic (C2, n = 34; similar weight loss, 
mechanic or iatrogenic origin); and non-cachectic (NC, n = 16). C2+NC were merged in the control group. 
The three groups showed significant differences in average prognostic inflammatory nutritional index (C1: 
26.4±23.4; C2: 5.4±5.6; NC: 0.37±0.5), C-reactive protein serum levels (C1: 6.6±2.1; C2: 2.4±2.2; NC: 1.0±2.0 
mg/dl), albumin serum levels (C1: 3.1±0.6; C2: 3.5±0.4; NC 3.7±0.6 g/dl), weight loss (C1: 22±8; C2: 15±6.7; 
NC 5±6%) and life expectancy (C1: 6.4±3.3; C2: 25±28; NC: 45±25 months). However, none of the chosen 
polymorphisms showed any statistically significant correlation with CACS. The complexity of the changes of the 
immune system in the chronic inflammation state associated with CACS is far greater than expected and further 
studies are required to identify genetic independent markers of progression toward CACS. 
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1. INTRODUCTION 
Cancer Anorexia-Cachexia Syndrome (CACS) is a 
dramatic and debilitating occurrence that can be 
observed at any stage of malignancy and has been 
described as a clinical syndrome accompanying cancer 
since ancient times (Bennani-Baiti and Walsh, 2009). 
We recently demonstrated that cancer patients with 
CACS have higher C-Reactive Protein (CRP) levels 
compared with non-cachectic cancer patients (Punzi et al., 
2012), thus reinforcing the hypothesis that the chronic 
inflammatory state commonly observed in advanced 
cancers is linked to the aetiology of CACS 
(MacDonald, 2011). Aberrant immune system activity 
is a crucial aspect of the chronic systemic 
inflammation associated with CACS and it triggers a 
vicious cycle leading to further tumour growth and 
metastases. Although the interconnections between aberrant 
immune system activity and CACS are multifaceted, two 
specific pathways appear to be prominent; the ubiquitin-
proteasome pathway (Camps et al., 2006) and the 
vitamin D axis that includes vitamin D, the 
polymorphic vitamin D receptor (VDR), the vitamin 
D-binding protein (or Gc-protein) and its derivative, 
Gc protein-derived Macrophage Activating Factor 
(GcMAF), one of the most potent stimuli of the 
immune system (Strohle et al., 2010; Ruggiero and 
Pacini, 2011).  
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Fig. 1. Angiotensin-Converting Enzyme (ACE) and Vitamin D Receptor (VDR) genotypes in cancer anorexia-cachexia syndrome 
As schematically illustrated in Fig. 1, the association 
between the ubiquitin-proteasome pathway, Angiotensin 
Converting Enzyme (ACE) and VDR polymorphic 
genotypes, CACS and the immune system is a complex 
one. In this regard, at the 2007 annual meeting of the 
American Society of Clinical Oncology, Vigano et al. 
(2007) presented a challenging work entitled “Angiotensin-
Converting Enzyme Gene Polymorphism (ACEGP) and 
Cancer Cachexia (CC): Is there a link?” (Vigano et al., 
2007). In fact, it had been previously demonstrated that 
angiotensin I (ATI)-induced protein degradation was 
inhibited by the ACE inhibitor imidapril and/or the 
proteasome inhibitors lactacystin or MG132 (Sanders et al., 
2005). In Addition, it was demonstrated that angiotensin II 
(ATII) suppressed hepatic expression of Insulin-Like 
Growth Factor-1 (IGF-1) (Delafontaine and Akao, 2006) 
and increased cortisol serum levels (Ortiz et al., 2010). 
These two events act synergistically on muscle protein 
breakdown with consequent liberation of free amino acids 
via the ubiquitin-proteasome pathway. Therefore, 
considering the pro-catabolic effects of ATII on skeletal 
muscle, mainly via the ubiquitin-proteasome pathway, our 
hypothesis was that ACE gene polymorphisms could be 
associated with different prognosis in CACS patients. 
If ACE gene polymorphisms may be associated with 
a pro-catabolic effect, VDR gene polymorphisms on 
their part could be associated with an anti-catabolic 
effect. In fact, activated VDR acts as a transcriptional 
factor forming a heterodimer with the retinoid-X 
receptor and then binding to response elements on DNA, 
resulting in expression or repression of specific target 
genes (Moore et al., 2006). Among these, the IGF-1 
transcriptional pathway falls under the target of VDR 
modulation (Jurutka et al., 2001). IGF-1, a potent 
anabolic signal, directly inhibits the ubiquitin-
proteasome system, thus, at least hypothetically, 
counteracting the effects of ACE product (Stitt et al., 
2004). The ubiquitin-proteasome pathway appears thus 
to be located at a critical control point with ACE and 
VDR gene polymorphic genotypes possibly associated 
with opposite effects on the anabolic/catabolic balance. 
Therefore, in this study we determined 
Insertion/Deletion (I/D) ACE gene polymorphism and FokI 
and BsmI VDR gene polymorphisms in cancer patients in 
order to establish whether specific polymorphic genotypes 
could be associated with the prognosis. 
2. MATERIALS AND METHODS 
After giving their informed consent, sixty-two cancer 
patients were randomly recruited in the Nutritional Unit 
of the Misericordia e dolce hospital in Prato, Italy. Age, 
gender, stage, primary cancer localization and ongoing 
therapy were randomly chosen. We divided the enrolled 
subjects into the following three groups: primary 
Cachectic (C1), secondary Cachectic (C2) and non-
Cachectic (NC). The ranking criteria followed the 
guidelines set by the Italian Association of Medical 
Oncology (AIOM) in 2007 and are summarized in Table 
1 (AIOM, 2008). Accordingly, we had 14 patients in the 
C1 group, 32 in the C2 group and 16 in the NC group.  
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Table 1. Criteria for diagnosis of primary and secondary 
CACS, AIOM 2007 
Primary CACS 
Loss ≥ 5% of pre-illness weight within the last 6 months plus 
Decreased muscle strength  
Fatigue  
Anorexia  
Low lean mass index   
Biochemichal alterations: 
Increase in cytokine levels 
Hb<12 mg/dl 
Albumin < 3.2 mg kg-1 
Additional criteria for diagnosis of secondary CACS 
CACS plus clinical evidence of 
Gastrointestinal obstruction  
Chemotherapeutic treatment, radiation therapy 
Post-interventional malabsorption sindrome 
CACS, cancer anorexia-cachexia syndrome; AIOM, 
Associazione Italiana di Oncologia Medica;  
Hb, haemoglobin 
 
As reported in Table 1, the diagnosis of cachexia 
followed the documented loss of 5% or more of body 
weight in the 6 months preceding the diagnosis of 
cancer. Despite the broad lack of consensus for this 
quantification, with many Authors assuming 
occurrence of CACS only after 10% body weight loss 
in 6 months, we postulated that in an actual clinical 
frame an early threshold was preferable. Secondary 
CACS depicted the frequent situation of a wasting 
syndrome derived from precise detectable causes. The 
two main tools to distinguish C1 from C2 were, 
therefore, targeted anamnesis and endoscopy/imaging. 
The unknowing patient, who involuntarily was losing 
weight with a conserved appetite or with a first 
manifestation of anorexia, was the prototype patient fitting 
the C1 criteria. The dyspeptic, dysphagic patient, who was 
losing weight after chemotherapy, surgery, radiation 
therapy, or because of severe stenosis at the level of the 
gastrointestinal tract, was a fitting model for C2. NC 
patients sometimes also lost weight. In this case, however, 
it was generally a therapeutic weight loss aiming to 
prevent complications in poly-morbid conditions, like 
heart failure, diabetes, respiratory distress.  
We analyzed the three groups as separate entities 
during the epidemiological study, but we reduced the last 
two to a single one, the non-primary CACS group (NC = 
C2+NC), for the study of polymorphic genotypes, 
considering this as the control group with no presumable 
genetic predisposition towards weight loss. Each 
enrolled patient underwent accurate clinical examination, 
blood collection and DNA sampling. The clinical data of 
interest included age, tumor type, stage, pre-illness 
weight and timing of weight loss. Weight measurement 
in the ambulatory unit concluded the routine. Venous 
blood samples were taken and serum levels of CRP, pre-
albumin, albumin and alpha-1-acid-protein were 
determined in the clinical laboratories of the hospital. We 
then calculated the Prognostic Inflammatory and 
Nutritional Index (PINI) score for each patient. 
Regrettably, approximately one of two patients taking part 
in the study deceased during the 2 year observation period. 
A retrospective analysis of life expectancy could therefore 
be traced, starting from the first day of cancer diagnosis. 
DNA sampling was done on finger prick samples of 
approximately 50 µl. DNA extraction and purification 
were performed by QIAamp® DNA Blood Mini Kit 
(QIAGEN S.p.a., Italy). Purified DNA was then 
examined for FokI and BsmI VDR gene polymorphism 
and I/D ACE gene polymorphism after polymerase chain 
reaction amplification (SuperMini Cycler®, Mj 
Research, Inc., USA) using specific primers and the 
AccuPrime Supermix Kit (Invitrogen, Carlsbad, CA, 
USA) (Punzi et al., 2012).  
Investigation of the ACE gene I/D polymorphism 
required no restriction enzymes; once amplified, the genetic 
sequence of interest had different lengths, depending on the 
presence (I) or absence (D) of the fragment 288 bp length. 
On the contrary, to determine the allelic characteristic of 
the VDR gene, each amplified DNA fragment was 
treated with appropriate restriction enzymes (Punzi et al., 
2012). The restriction products of FokI and BsmI were 
sorted as F and f and B and b respectively, where capital 
letters indicate an absence of restriction sites and lower-
case letters indicate their presence. 
3. RESULTS 
As expected, the clinical threefold subdivision of 
patients produced radically different groups in terms of 
average weight loss, intensity of inflammatory reaction, 
nutritional status, PINI score and life expectancy. It is 
important to notice that differences in average age and 
stage proved to be non-significant; we consider this 
observation of clinical relevance since it reinforces the 
notion that CACS is a stochastic event. C1 patients had 
the highest systemic inflammation, lowest nutritional 
status and dramatically poorest prognosis (Table 2). As 
previously described by our research group (Punzi et al., 
2012), CRP proved to be one of the most reliable and 
economic blood markers for CACS that a standard 
clinical laboratory can study (Mahmoud and Rivera, 
2002). A standard nutritional status assessment usually 
includes the determination of albumin serum level, despite 
the open discussion regarding which albumin threshold 
should be chosen for the diagnosis of malnutrition.  
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Table 2. Patients’ data 
  C1  C2   NC 
 ------------------------ -------------------------- ----------------------------- 
  Mean ± SD n Mean ± SD n Mean ± SD N 
Age (years) 66.9±8.66 14 66.8±11.6 32 59.9±10.6 16 
Stage 3.6±0.6 14 3.6±0.6  32 3.4±0.9 16 
Gender 43% F 14 37% F 32 50% F 16 
%Weight loss in 6 months  21.0±7.9 14 15.4±6.7 32 5.1±6.2 16 
CRP (mg/dl) 6.6±6.3 9 2.4±2.2 29 1.0±2.0 16 
Albumin (mg/dl) 3.1±0.6 10 3.5±0.4 29 3.7±0.6 15 
PINI score 28 9 4 20 0.98 11 
Average survival time after 6.4±3.3 9 26.1±27.6 12 45.3±25.0 7 
diagnosis of cancer (months) 
C1, high risk; C2, intermediate risk; C3, normal. F, female 
 
Table 3. Genotype frequencies in primary CACS and control 
groups 
  C2 + NC C1  
 VDR gene Genotype (n = 48)  (n = 14) p 
polimorphysms 
FokI FF 0.28 0.36 0.81 
 Ff 0.64 0.57 
 ff 0.08 0.07 
BsmI BB 0.10 0.07 0,87 
 Bb 0.53 0.50 
 bb 0.37 0.43 
ACE gene DD 0.45 0.50 0,62 
polymorphisms ID 0.38 0.43 
 II 0.17 0.07 
C1, primary cancer anorexia-cachexia syndrome (CACS); C2 + 
NC, no presumable genetic disposition towards CACS; VDR, 
vitamin D receptor; ACE, angiotensin-converting enzyme 
 
Table 4. Allele frequencies in primary CACS and control 
groups 
VDR  C2 + NC C1  
polymorphisms Alleles (n = 48) (n 14) p  
FokI F 0.60 0.68 0.64 
 f 0.40 0.32 
BsmI B 0.36 0.32 0.63 
 b 0.64 0.68 
ACE polymorphisms D 0.64 0.71 0.41 
 I 0.36 0.29 
C1, primary cancer anorexia-cachexia syndrome (CACS); C2 + 
NC, no presumable genetic disposition towards CACS; VDR, 
vitamin D receptor; ACE, angiotensin-converting enzyme 
 
We set the cutoff for malnutrition at 3.5 mg/dl albumin 
(Harrison, 1998) and at 3.2 mg/dl for a diagnosis of 
severe malnutrition. The critics for albumin as a 
nutritional marker mainly revolve around two 
observations, namely that hepatic protein synthesis 
reprioritization in the acute inflammatory response is per 
se sufficient to precipitate albumin serum levels, despite 
normal nutritional status and that compensatory 
mechanisms keep albumin levels high during prolonged 
insufficient protein intake through depletion of skeletal 
muscle tissue. Although high CRP levels are good 
indexes for systemic inflammation, poor levels of 
albumin cannot distinguish starvation from chronic 
systemic inflammation. Therefore, in order to draw a 
comprehensive picture of the three patient groups, we 
combined the collected blood values into a single 
score, the PINI score a reliable tool capable of 
estimating the risk of complications during 
hospitalization of chronically ill patients (Yates, 1980). 
PINI is calculated by dividing the product of serum 
alpha-1-glycoprotein and CRP levels by that of albumin 
and pre-albumin. 
Prognostic Inflammatory and Nutritional Index:  
 
( ) ( )
( ) ( )
alpha 1 acid glycoprotein mg / dl  x CRP mg / dl
albumin g / dl  x prealbumin mg / dl
− −
 
 
Where: 
PINI > 30 = predicts a very high risk of complications 
during hospitalization [21-30] predicts a 
high risk of complications during 
hospitalization  
[11-20] = Predicts an intermediate risk 
[1-10] = Predicts a low risk 
< 1 = Normal 
 
As reported in Table 2, the C1 group fell in the high-
risk category, C2 in the intermediate and NC in the 
normal. The survival rate of the three groups confirmed 
the nutritional prognosis.  
Given the significant differences of the three 
populations, in order to investigate the genetic 
predisposition towards CACS, we isolated the C1 group 
(n = 14) and created a reference group merging C2 and 
NC pools (n = 48), which presumably had no genetic 
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predisposition towards CACS. The study of genotypic 
frequency results from the proportion between the 
number of subjects harboring a specific genotype and the 
total number of subjects. Below is the formula for the 
frequency of an exemplificative FF genotype; genotype 
frequencies in primary CACS and control groups are 
shown in Table 3: 
 
( )
FF genotype  number of FF subjects
/total examined subjects FF  Ff  ff
=
+ +
 
 
Comparing the genotype frequencies of the VDR 
gene between the group of primary cachectic patients 
and the control group, no significant difference could be 
found (p>0.05). Comparing the genotype frequencies of 
the ACE gene between the same pools of patients, the 
same result was obtained. The distribution of allele 
frequencies was then calculated both for the VDR and 
ACE gene polymorphisms on the basis of genotype 
frequencies (Table 4). Below is the formula for 
calculating allele frequency:  
 
F allele frequency genotype 
FF frequency ½ Ff genotype frequency
f allele frequency 1- F allele frequency
=
+
=
 
 
Allele distribution for both ACE and VDR genes 
showed no significant difference between the primary 
cachectic group and the control group, for any of the 
studied polymorphisms (Table 4). 
4. DISCUSSION 
Genetics is a promising field for the study of 
predisposition towards CACS, because CACS itself is an 
apparently stochastic event, occurring at random among 
individuals who are not significantly different in terms of 
age, stage and tumor type as confirmed in this study. 
Nevertheless, according to the results of our 
observations, the answer to the question “Angiotensin-
Converting Enzyme Gene Polymorphism (ACEGP) and 
Cancer Cachexia (CC): Is there a link?” appears to be 
negative. In fact, both allele frequencies and genotypic 
frequencies of the ACE gene polymorphisms were not 
significantly associated with clinical progression of 
CACS. A similar conclusion can be drawn for VDR gene 
polymorphisms. These conclusions notwithstanding, we 
cannot rule out the possibility that different results could 
be obtained by increasing the size of the sample to be 
examined. In addition, although the random selection of 
patients was a precise choice of this study reflecting the 
clinical actuality of most hospitals, we cannot rule out 
the possibility that in certain sub-groups of CACS 
patients the results might be different.  
5. CONCLUSION 
In conclusion, our study demonstrates that the 
complexity of the changes of the immune system in the 
chronic inflammation state associated with CACS 
(Khatami, 2011) is far greater than expected and further 
studies are required to identify genetic independent 
markers of progression toward CACS that, as of today, 
remains a stochastic, unpredictable event.  
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